Medicus Pharma (MDCX) Competitors $2.67 -0.28 (-9.49%) As of 06/11/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock MDCX vs. SPRO, MOLN, IKT, IMAB, BDTX, EPRX, VTYX, FTLF, RAPT, and NKTXShould you be buying Medicus Pharma stock or one of its competitors? The main competitors of Medicus Pharma include Spero Therapeutics (SPRO), Molecular Partners (MOLN), Inhibikase Therapeutics (IKT), I-Mab (IMAB), Black Diamond Therapeutics (BDTX), Eupraxia Pharmaceuticals (EPRX), Ventyx Biosciences (VTYX), FitLife Brands (FTLF), RAPT Therapeutics (RAPT), and Nkarta (NKTX). These companies are all part of the "pharmaceutical products" industry. Medicus Pharma vs. Its Competitors Spero Therapeutics Molecular Partners Inhibikase Therapeutics I-Mab Black Diamond Therapeutics Eupraxia Pharmaceuticals Ventyx Biosciences FitLife Brands RAPT Therapeutics Nkarta Spero Therapeutics (NASDAQ:SPRO) and Medicus Pharma (NASDAQ:MDCX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, community ranking, valuation and profitability. Do insiders and institutionals hold more shares of SPRO or MDCX? 25.6% of Spero Therapeutics shares are owned by institutional investors. 5.5% of Spero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Do analysts recommend SPRO or MDCX? Spero Therapeutics presently has a consensus target price of $5.00, suggesting a potential upside of 78.57%. Medicus Pharma has a consensus target price of $23.50, suggesting a potential upside of 780.15%. Given Medicus Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Medicus Pharma is more favorable than Spero Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spero Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Medicus Pharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50 Is SPRO or MDCX more profitable? Spero Therapeutics has a net margin of 3.30% compared to Medicus Pharma's net margin of 0.00%. Spero Therapeutics' return on equity of 4.03% beat Medicus Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Spero Therapeutics3.30% 4.03% 2.21% Medicus Pharma N/A N/A N/A Does the MarketBeat Community believe in SPRO or MDCX? Spero Therapeutics received 198 more outperform votes than Medicus Pharma when rated by MarketBeat users. However, 84.62% of users gave Medicus Pharma an outperform vote while only 69.67% of users gave Spero Therapeutics an outperform vote. CompanyUnderperformOutperformSpero TherapeuticsOutperform Votes20969.67% Underperform Votes9130.33% Medicus PharmaOutperform Votes1184.62% Underperform Votes215.38% Which has stronger earnings & valuation, SPRO or MDCX? Spero Therapeutics has higher revenue and earnings than Medicus Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpero Therapeutics$28.30M5.53$22.81M-$1.28-2.19Medicus PharmaN/AN/AN/AN/AN/A Does the media prefer SPRO or MDCX? In the previous week, Medicus Pharma had 1 more articles in the media than Spero Therapeutics. MarketBeat recorded 6 mentions for Medicus Pharma and 5 mentions for Spero Therapeutics. Spero Therapeutics' average media sentiment score of 1.12 beat Medicus Pharma's score of 0.27 indicating that Spero Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spero Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medicus Pharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral SummarySpero Therapeutics beats Medicus Pharma on 8 of the 13 factors compared between the two stocks. Get Medicus Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MDCX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MDCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MDCX vs. The Competition Export to ExcelMetricMedicus PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.24M$6.85B$5.57B$8.63BDividend YieldN/A2.56%5.28%4.18%P/E RatioN/A8.7827.1220.06Price / SalesN/A255.64412.30157.10Price / CashN/A65.8538.2534.64Price / BookN/A6.557.064.70Net IncomeN/A$143.93M$3.23B$247.88M7 Day Performance-1.48%3.84%2.86%2.63%1 Month Performance-45.06%11.20%9.07%6.36%1 Year PerformanceN/A4.18%31.45%14.05% Medicus Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MDCXMedicus Pharma2.0048 of 5 stars$2.67-9.5%$23.50+780.1%N/A$36.24MN/A0.00N/AAnalyst ForecastHigh Trading VolumeSPROSpero Therapeutics3.8843 of 5 stars$2.66+0.8%$5.00+88.0%+88.6%$148.72M$28.30M38.01150Positive NewsShort Interest ↑High Trading VolumeMOLNMolecular Partners2.8821 of 5 stars$3.65+1.7%$12.00+228.8%-27.0%$147.37M$2.23M-1.70180IKTInhibikase Therapeutics1.4975 of 5 stars$1.98-2.5%$6.50+228.3%+22.9%$147.20M$260K-0.746Positive NewsIMABI-Mab3.2077 of 5 stars$1.79-4.3%$5.50+207.3%+33.9%$146.17M$3.27M0.00380High Trading VolumeBDTXBlack Diamond Therapeutics3.4677 of 5 stars$2.54+1.6%$14.60+474.8%-61.1%$144.43M$70M-1.9190EPRXEupraxia Pharmaceuticals2.2996 of 5 stars$3.97-2.5%$10.50+164.5%+38.9%$142.32MN/A-5.5129VTYXVentyx Biosciences2.6791 of 5 stars$1.99flat$10.00+402.5%-23.8%$141.61MN/A-0.8430News CoveragePositive NewsOptions VolumeFTLFFitLife Brands4.1971 of 5 stars$14.46+0.8%$20.50+41.8%-5.9%$135.79M$63.86M17.1120Positive NewsShort Interest ↑RAPTRAPT Therapeutics3.9111 of 5 stars$1.02+3.2%$3.00+194.1%-70.2%$134.94M$1.53M-0.3780NKTXNkarta3.667 of 5 stars$1.89+6.8%$14.67+676.0%-69.2%$134.11MN/A-1.01140Analyst Forecast Related Companies and Tools Related Companies Spero Therapeutics Alternatives Molecular Partners Alternatives Inhibikase Therapeutics Alternatives I-Mab Alternatives Black Diamond Therapeutics Alternatives Eupraxia Pharmaceuticals Alternatives Ventyx Biosciences Alternatives FitLife Brands Alternatives RAPT Therapeutics Alternatives Nkarta Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MDCX) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredTrump Makes Major Crypto AnnouncementPay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift ...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicus Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medicus Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MDCX Stock Free MDCX Stock Alerts